MDM2 rs2279744: Understanding the SNP309 Promoter Variant
The rs2279744 variant, commonly known as SNP309, is a single nucleotide polymorphism located in the promoter region of the MDM2 gene. It is widely studied for its potential to influence MDM2 protein expression and the subsequent regulation of the p53 tumor suppressor pathway.
What each genotype means
Baseline MDM2 expression
This genotype is considered the reference state for the MDM2 promoter region. Research indicates that individuals with this genotype typically exhibit lower levels of MDM2 protein compared to those carrying the G allele, which may result in a more robust p53 stress response pathway. Associations with cancer risk are inconsistent across studies, and this variant should not be used to predict individual health outcomes.
This is a common genotype, though its frequency varies significantly by ancestry, with higher prevalence in many non-African populations.
Intermediate MDM2 expression
Carrying one copy of the G allele is associated with increased affinity for the Sp1 transcription factor, which can lead to elevated MDM2 protein levels and potential attenuation of the p53 tumor suppressor pathway. Studies on the clinical impact of this genotype are highly contradictory, with some suggesting increased cancer susceptibility and others finding no significant effect or even protective associations depending on the cancer type and population studied.
This heterozygous genotype is frequently observed in global populations, often representing a significant portion of the population distribution.
Elevated MDM2 expression
This genotype is associated with the highest levels of MDM2 protein expression due to enhanced Sp1 binding in the MDM2 promoter. While some research links this genotype to earlier onset or more aggressive characteristics in certain cancers, other studies report no association or even protective effects in different contexts. Because the evidence is highly variable and dependent on specific environmental and genetic backgrounds, this result does not provide a definitive assessment of personal health risk.
This genotype is less common than the T/T or T/G genotypes in many populations, though it remains a well-documented variant.
What is rs2279744?
The rs2279744 variant is a single nucleotide polymorphism (SNP) where a thymine (T) is replaced by a guanine (G) in the promoter region of the MDM2 gene. Because this change occurs in the promoter—the "on-off switch" area of a gene—it can alter how much protein the cell produces. This specific variant is frequently referred to in scientific literature as SNP309. It sits within the P2 promoter of the MDM2 gene, a critical location that controls the gene's activity in response to cellular stress. Researchers have focused on this site for decades because of its potential to disrupt the delicate balance of proteins that protect the body from damaged or abnormal cells.
The Role of the MDM2 Gene
The MDM2 gene provides instructions for making a protein that acts as a primary negative regulator of p53. The p53 protein is often called the "guardian of the genome" because it prevents cells from dividing uncontrollably by triggering repair mechanisms or programmed cell death (apoptosis) when DNA is damaged. MDM2 keeps p53 levels in check by binding to it and marking it for degradation. When the MDM2 promoter is altered by variants like rs2279744, it may lead to higher levels of MDM2 protein. Increased MDM2 can potentially dampen the p53 response, theoretically making it harder for the body to eliminate cells that have accumulated genetic errors. This interaction is a central focus in understanding how cellular stress responses are managed.
Research and Associations
Scientific research has investigated whether the G-allele of rs2279744 is associated with an increased risk of various cancers, including lung, breast, and endometrial cancers. Some studies suggest that individuals carrying the G-allele may have an earlier onset of certain tumors or altered survival outcomes in conditions like chronic lymphocytic leukemia. However, the evidence is complex and often conflicting; many meta-analyses show that the association varies significantly by population, tumor type, and environmental factors like smoking or radiation exposure. It is important to note that this variant is considered a susceptibility marker rather than a direct cause of disease. Because results are inconsistent across different studies, the clinical significance of this SNP remains a subject of ongoing investigation rather than a definitive diagnostic tool.
Population Frequency
The rs2279744 variant is considered a common polymorphism across global populations. Both the T and G alleles are found at significant frequencies, meaning that a large portion of the general population carries at least one copy of the G-allele. Because it is so common, it is not considered a rare mutation but rather a normal variation in the human genetic landscape.
What This Means for You
If you have learned your genotype for rs2279744, it is important to understand that this information is primarily used in research settings to study population-level trends. Having a specific genotype does not mean you will develop a specific disease, nor does it provide a clear medical prognosis. Genetic associations are statistical in nature and do not account for the vast array of lifestyle, environmental, and other genetic factors that influence health. You cannot use this information to diagnose yourself or predict your future health. If you have concerns about your family history of cancer or your personal health risks, the most appropriate step is to consult with a healthcare professional or a genetic counselor who can evaluate your entire health profile.
How common is this variant?
The rs2279744 variant is a common polymorphism found globally, with both the T and G alleles appearing frequently across diverse ancestral groups.
Frequently asked questions
Is rs2279744 a cancer-causing mutation?
No, rs2279744 is a common genetic variant, not a disease-causing mutation. While some research suggests it may act as a susceptibility marker that influences cancer risk, it is not a direct cause of cancer.
Should I get tested for MDM2 rs2279744?
There is currently no clinical recommendation to test for this variant. Because the results do not provide actionable medical guidance, testing is generally limited to scientific research studies.
Can I change my risk if I have the G-allele?
Genetic variants are fixed, but your overall health risk is influenced by many factors. Focusing on established health behaviors, such as regular screenings and avoiding known environmental carcinogens, is the best way to manage health regardless of your genotype.
Does this variant affect how I respond to medication?
There is no standard clinical evidence that rs2279744 dictates medication response. Always discuss any concerns about your medications or treatment plans with your doctor or pharmacist.
Sources & further reading
Educational information only, last refreshed 10/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2279744?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29